Trial: 202105158

A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics,
and Immunogenicity of MT-6402 in Subjects with Advanced Solid Cancer That Expresses PD-L1


I (Cancer Control)

Principal Investigator

Van Tine, Brian

Disease Site

Brain and Nervous System; Breast; Colon; Esophagus; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, Skin; Other Endocrine System; Other Urinary; Ovary; Pancreas; Rectum; Small Intestine; Soft Tissue; Thyroid; Urinary Bladder

Learn more about this study at: